BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6343725)

  • 1. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ; Van Hazel G; Reynolds PM; Lemish WM; Holman CD
    J Surg Oncol; 1983 Jun; 23(2):114-6. PubMed ID: 6343725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
    Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical adjuvant therapy for malignant melanoma.
    Pinsky CM; Oettgen HF
    Surg Clin North Am; 1981 Dec; 61(6):1259-66. PubMed ID: 7031933
    [No Abstract]   [Full Text] [Related]  

  • 7. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL; Eilber FR; Holmes EC; Ramming KP
    Aust N Z J Surg; 1978 Feb; 48(1):49-52. PubMed ID: 276348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.
    Eilber FR; Morton DL; Holmes EC; Sparks FC; Ramming KP
    N Engl J Med; 1976 Jan; 294(5):237-40. PubMed ID: 1244548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical administration of BCG-immunotherapy in malignant melanoma (author's transl)].
    Wätzig V; Knopf B
    Arch Geschwulstforsch; 1979; 49(2):140-5. PubMed ID: 475550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy of malignant melanoma.
    Vosika GJ
    Minn Med; 1979 Jul; 62(7):515-7. PubMed ID: 386072
    [No Abstract]   [Full Text] [Related]  

  • 11. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Deutschmann KE; Peter HH; Schultheis W; Deicher H
    Tumori; 1977; 63(3):303-7. PubMed ID: 898298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical treatment of malignant melanoma.
    Rosenberg SA
    Cancer Treat Rep; 1976 Feb; 60(2):159-63. PubMed ID: 769968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
    N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
    Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
    Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCG immunotherapy as a systemic adjunct to surgery in malignant melanoma.
    Morton DL; Eilber FR; Holmes EC; Sparks FC; Ramming K
    Med Clin North Am; 1976 May; 60(3):431-9. PubMed ID: 1271888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
    Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
    Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
    Fisher RI; Terry WD; Hodes RJ; Rosenberg SA; Makuch R; Gordon HG; Fisher SG
    Surg Clin North Am; 1981 Dec; 61(6):1267-77. PubMed ID: 7031934
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival after malignant melanoma in a black child. A case report and review of the literature.
    Moritz MW; Wallack MK
    Am J Clin Oncol; 1984 Oct; 7(5):545-9. PubMed ID: 6507376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.